blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4583867

EP4583867 - SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  13.06.2025
Database last updated on 21.03.2026
FormerThe international publication has been made
Status updated on  15.03.2024
Most recent event   Tooltip14.11.2025Change: Validation statespublished on 17.12.2025  [2025/51]
14.11.2025Change - extension statespublished on 17.12.2025  [2025/51]
Applicant(s)For all designated states
Latigo Biotherapeutics, Inc.
1300 Rancho Conejo Blvd., Suite 305
Thousand Oaks, CA 91320 / US
[2025/29]
Inventor(s)01 / BAJJI, Ashok
Thousand Oaks, CA 91320 / US
02 / KAUFMAN, Michael, D.
Thousand Oaks, CA 91361 / US
03 / BALKOVEC, James, Michael
Martinsville, NJ 08836 / US
 [2025/29]
Representative(s)HGF
HGF Limited
4th Floor, 1 City Square
Leeds LS1 2ES / GB
[N/P]
Former [2025/29]HGF
HGF Limited
1 City Walk
Leeds LS11 9DX / GB
Application number, filing date23863823.308.09.2023
[2025/29]
WO2023US32280
Priority number, dateUS202263405094P09.09.2022         Original published format: US 202263405094 P
US202263405096P09.09.2022         Original published format: US 202263405096 P
US202263405120P09.09.2022         Original published format: US 202263405120 P
US202263405151P09.09.2022         Original published format: US 202263405151 P
[2025/29]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2024054622
Date:14.03.2024
Language:EN
[2024/11]
Type: A2 Application without search report 
No.:EP4583867
Date:16.07.2025
Language:EN
The application published by WIPO in one of the EPO official languages on 14.03.2024 takes the place of the publication of the European patent application.
[2025/29]
Search report(s)International search report - published on:US18.04.2024
ClassificationIPC:A61K31/395, A61K31/166, A61K31/44, A61K31/167, A61K31/4995, A61K31/33
[2025/29]
CPC:
C07D213/81 (EP,IL,KR); C07D213/82 (EP,IL,KR); A61K31/444 (KR);
A61P11/14 (KR); A61P17/04 (KR); A61P29/00 (KR);
C07C381/10 (KR); C07D213/65 (KR); C07D213/66 (EP,IL);
C07D213/75 (EP,IL,KR); C07D237/24 (EP,IL,KR); C07D401/04 (EP,IL,KR);
C07D401/12 (EP,IL,KR); C07D401/14 (EP,IL,KR); C07D405/14 (EP,IL,KR);
C07D417/14 (KR); C07D513/14 (EP,IL) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   ME,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2025/29]
TitleGerman:NATRIUMKANALBLOCKIERENDE VERBINDUNGEN, DERIVATE DAVON UND VERFAHREN ZU DEREN VERWENDUNG[2025/29]
English:SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE[2025/29]
French:COMPOSÉS BLOQUANT LES CANAUX SODIQUES, LEURS DÉRIVÉS ET LEURS PROCÉDÉS D'UTILISATION[2025/29]
Entry into regional phase06.02.2025National basic fee paid 
06.02.2025Search fee paid 
06.02.2025Designation fee(s) paid 
06.02.2025Examination fee paid 
Examination procedure06.02.2025Examination requested  [2025/29]
16.10.2025Amendment by applicant (claims and/or description)
Fees paidRenewal fee
29.09.2025Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[A] US10647661  (AHMAD NADIA et al.) [A] 1, 5-7, 9-10, 17, 19, 23- 24, 27, 29 * , entire document, especially col 4, In 5-67; col 5-7 *
 [A] WO2009049183  (VERTEX PHARMA et al.) [A] 1, 5-7, 9-10, 17, 19, 23-24, 27, 29 * , entire document, especially para[0001], [0016]-[0018] *
 [A] US2012202817  (HONDA TAKAHIRO et al.) [A] 1, 5-7, 9-10, 17, 19, 23-24, 27, 29 * , entire document, especially para[0009], [0014], [0042] *
 [A] WO2022094244  (CALICO LIFE SCIENCES LLC et al.) [A] 1, 5-7, 9-10, 17, 19, 23-24, 27, 29 * , entire document, especially page 2, In 15-32; pages 3-6 *
 [A, P] WO2023154519  (ACCENT THERAPEUTICS INC et al.) [A, P] 1, 5-7, 9-10, 17, 19, 23-24, 27, 29 * , entire document, especially page 2, In 5-29; pages 3-7; page 89, In 13-21 *
 [A]   DATABASE PUBCHEM COMPOUND 16 March 2019 (2019-03-16), ANONYMOUS: "N-(3-carbamoylphenyl)-3-[2methoxy-4-(trifluoromethoxy)phenoxy]-5-(trifluoromethyl)pyridine-2carboxamide", XP093163413, Database accession no. 137406440 [A] 1, 5-7, 9-10, 17, 19, 23-24, 27, 29 * , entire document, especially page 2, compound listed *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.